6.99
-0.07(-0.99%)
Currency In USD
| Previous Close | 7.06 |
| Open | 7.17 |
| Day High | 7.19 |
| Day Low | 6.9 |
| 52-Week High | 21.98 |
| 52-Week Low | 1.8 |
| Volume | 52,547 |
| Average Volume | 650,385 |
| Market Cap | 60.83M |
| PE | -3.22 |
| EPS | -2.17 |
| Moving Average 50 Days | 8.52 |
| Moving Average 200 Days | 8.34 |
| Change | -0.07 |
If you invested $1000 in CervoMed Inc. (CRVO) 10 years ago, it would be worth $0.03 as of June 20, 2025 at a share price of $6.99. Whereas If you bought $1000 worth of CervoMed Inc. (CRVO) shares 5 years ago, it would be worth $92.28 as of June 20, 2025 at a share price of $6.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
GlobeNewswire Inc.
Jun 10, 2025 12:00 PM GMT
Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- CervoMed
CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference
GlobeNewswire Inc.
May 07, 2025 12:00 PM GMT
BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participat
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025
GlobeNewswire Inc.
Apr 02, 2025 11:00 AM GMT
During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CG